http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0857020-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d202e9e866984fe229f6facc38f1d740 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2004 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2077 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-438 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4465 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4523 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-438 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38 |
| filingDate | 1996-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_688cc7f459af6373e301a1ae0ea4238b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c95cf50a06547fa0bedfbad9aeaf34c5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17ba5dfce69c2ab690ee8aeb155169c3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f3ea0f6e170b8b7ac6218c60a218a477 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db61bfd736638d40a6285f2212d153ea |
| publicationDate | 1998-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0857020-A1 |
| titleOfInvention | Wet granulation formulation of a growth hormone secretagogue |
| abstract | The present invention relates to a pharmaceutical composition and a process for the preparation of a tablet containing a growth hormone secretagogue as the active ingredient. The tablet is prepared by forming a powder blend of the active ingredient N-[1(R)-[(1,2-dihydro-1-methanesulfonyl-spiro[3H-indole-3,4'-piperdin]-1'-yl)carbonyl]-2-(phenylmethyl-oxy)ethyl]-2-amino-2-methyl-propanamide, or a pharmaceutically acceptable salt thereof, in particular the methanesulfonate salt, with a binder/diluent, a first diluent, a second diluent, a first portion of a disintegrant, and a lubricant; wet granulating the powder blend with a solution of ethanol/water to form granules; drying the granules to remove the ethanol/water; adding a second portion of a disintegrant; lubricating the granules; and compressing the dried granules into the desired tablet form. The present invention further relates to a novel amorphous form of the compound N-[1(R)-[(1,2-dihydro-1-methanesulfonyl-spiro[3H-indole-3,4'-piperdin]-1'-yl)carbonyl]-2-(phenylmethyl-oxy)ethyl]-2-amino-2-methylpropanamide methanesulfonate which is produced directly as a result of the process of tablet formulation. |
| priorityDate | 1995-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 682.